Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412
The DOI matches its Crossref record; 17 of the 18 references it cites were found in a registry or an index.
Abstract
Six healthy young male volunteers at a contract research organization were enrolled in the first phase 1 clinical trial of TGN1412, a novel superagonist anti-CD28 monoclonal antibody that directly stimulates T cells. Within 90 minutes after receiving a single intravenous dose of the drug, all six volunteers had a systemic inflammatory response characterized by a rapid induction of proinflammatory cytokines and accompanied by headache, myalgias, nausea, diarrhea, erythema, vasodilatation, and hypotension. Within 12 to 16 hours after infusion, they became critically ill, with pulmonary infiltrates and lung injury, renal failure, and disseminated intravascular coagulation. Severe and unexpected depletion of lymphocytes and monocytes occurred within 24 hours after infusion. All six patients were transferred to the care of the authors at an intensive care unit at a public hospital, where they received intensive cardiopulmonary support (including dialysis), high-dose methylprednisolone, and an anti-interleukin-2 receptor antagonist antibody. Prolonged cardiovascular shock and acute respiratory distress syndrome developed in two patients, who required intensive organ support for 8 and 16 days. Despite evidence of the multiple cytokine-release syndrome, all six patients survived. Documentation of the clinical course occurring over the 30 days after infusion offers insight into the systemic inflammatory response syndrome in the absence of contaminating pathogens, endotoxin, or underlying disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Although the solid phase assay does not replicate in vivo presentation of TGN1412, which is not fully understood, it does induce substantial cytokine release equivalent to that reported in trial volunteers.”
From Severity of the TGN 1412 trial disaster cytokine storm correlated with IL‐2 release (2013) · cites this paper as [2]
Experimental — accuracy not yet measuredIn the citing paper
“In 2006, a life-threatening 'cytokine storm', not predicted by pre-clinical safety testing, rapidly occurred in all six healthy volunteers during the phase I clinical trial of the CD28 superagonist monoclonal antibody (mAb) TGN1412.”
From Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T‐cells (2010) · cites this paper as Suntharalingam et al., 2006
In the citing paper
“One of the most striking features of the TGN1412-mediated 'cytokine storm' observed in humans was substantial TNF-a release within the first hour of infusion followed by dramatic increases in IFN-g, IL-2, IL-6, IL-8 and IL-10 plasma concentrations within 4 h (Suntharalingam et al., 2006).”
From Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T‐cells (2010) · cites this paper as Suntharalingam et al., 2006
In the citing paper
“Concentrations of TNF-a measured by ELISA in culture supernatants collected 24 h after in vitro TGN1412 stimulation were also consistent with the peak concentrations reported in trial volunteers, with the considerable caveat that a comparison is being made between an in vitro system and an in vivo response.”
From Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T‐cells (2010) · cites this paper as Suntharalingam et al., 2006
In the citing paper
“However, despite similar in vitro expression kinetics for IFN-g following TGN1412 stimulation, the concentrations of IFN-g were far lower than TNF-a responses in vitro, and an order of magnitude lower than concentrations of IFN-g predicted from in vivo responses in trial participants (Suntharalingam et al., 2006).”
From Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T‐cells (2010) · cites this paper as Suntharalingam et al., 2006
35 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cited works that were retracted
Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.
A note, not an issue: for example, a cited work that was retracted only after this paper was published, which its authors could not have known.
In the paper
“10.1073/pnas.0501997102”
Cited work 10.1073/pnas.0501997102 · retracted 2009-07-09 · notice 10.1073/pnas.0906977106 · this paper published 2006-09-07
Citations
Cites
1 retracted
Gon, Y., Wood, M. R., Kiosses, W. B., Jo, E., Sanna, M. G., Chun, J., & Rosen, H. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501997102 · Cited by 128
RetractedBone, R. C., Balk, R. A., Cerra, F. B., Dellinger, R. P., Fein, A. M., Knaus, W. A., Schein, R. M. H., & Sibbald, W. J. (1992) · Chest · doi:10.1378/chest.101.6.1644 · Cited by 13,198
Bernard, G. R., Artigas, A., Brigham, K. L., Carlet, J., Falke, K., Hudson, L., Lamy, M., Legall, J. R., Morris, A., & Spragg, R. (1994) · American journal of respiratory and critical care medicine · doi:10.1164/ajrccm.149.3.7509706 · Cited by 6,746
Sepsis-Induced Apoptosis Causes Progressive Profound Depletion of B and CD4+ T Lymphocytes in Humans
Hotchkiss, R. S., Tinsley, K. W., Swanson, P. E., Schmieg, R. E., Hui, J. J., Chang, K. C., Osborne, D. F., Freeman, B. D., Cobb, J. P., Buchman, T. G., et al. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.11.6952 · Cited by 934
Clinical risks for development of the acute respiratory distress syndrome.
Hudson, L. D., Milberg, J. A., Anardi, D., & Maunder, R. J. (1995) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.151.2.7842182 · Cited by 890
Brivet, F. G., Kleinknecht, D. J., Loirat, P., & Landais, P. J. M. (1996) · Critical Care Medicine · doi:10.1097/00003246-199602000-00003 · Cited by 879
Winkler, U., Jensen, M., Manzke, O., Schulz, H., Diehl, V., & Engert, A. (1999) · Blood · doi:10.1182/blood.v94.7.2217.419k02_2217_2224 · Cited by 657
Wing, M. G., Moreau, T., Greenwood, J., Smith, R. M., Hale, G., Isaacs, J., Waldmann, H., Lachmann, P. J., & Compston, A. (1996) · Journal of Clinical Investigation · doi:10.1172/jci119110 · Cited by 257
Beyersdorf, N., Gaupp, S., Balbach, K., Schmidt, J., Toyka, K. V., Lin, C.-H., Hanke, T., Hünig, T., Kerkau, T., & Gold, R. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20051060 · Cited by 203
Cited by
Items 501–600 of 2,162
Cytokine storm in a mouse model of IgG-mediated hemolytic transfusion reactions
Hod, E. A., Cadwell, C. M., Liepkalns, J. S., Zimring, J. C., Sokol, S. A., Schirmer, D. A., Jhang, J. S., & Spitalnik, S. L. (2008) · Blood · doi:10.1182/blood-2008-01-132092 · Cited by 54
“Human case reports also suggest that cytokine storm in other settings produces SIRS and multiorgan failure.(4) In addition, cytokines were implicated in one human IgG-mediated HTR(5) and in patients with autoimmune thrombocytopenic purpura (AITP), who develop hemolysis after receiving anti-Rh(D).”
BackgroundConvalescent transfusion for pandemic influenza: preparing blood banks for a new plasma product?
Leider, J. P., Brunker, P. A. R., & Ness, P. M. (2010) · Transfusion · doi:10.1111/j.1537-2995.2010.02590.x · Cited by 54
“However, severe reactions can occur, including lifethreatening cytokine storm.(49) Depending on the degree of chimerism of the MoAb and humanization methods,(50,51) allergic reactions may also ensue, but the severity of the allergic reaction is reduced by increasing use of humanized MoAbs.”
BackgroundRaj, R. V., Hamadani, M., Szabó, A., Pasquini, M. C., Shah, N. N., Drobyski, W. R., Shaw, B. E., Saber, W., Rizzo, J. D., Jerkins, J. H., et al. (2018) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2018.04.010 · Cited by 58
Gut-on-chip for ecological and causal human gut microbiome research
Moossavi, S., Arrieta, M., Sanati‐Nezhad, A., & Bishehsari, F. (2022) · Trends in Microbiology · doi:10.1016/j.tim.2022.01.014 · Cited by 55
Tibbitts, J., Cavagnaro, J., Haller, C., Marafino, B. J., Andrews, P., & Sullivan, J. T. (2010) · Regulatory toxicology and pharmacology : RTP · doi:10.1016/j.yrtph.2010.06.007 · Cited by 48
Schabowsky, R.-H., Elpek, K. G., Madireddi, S., Sharma, R. K., Yolcu, E. S., Bandura‐Morgan, L., Miller, R. E., MacLeod, K. J., Mittler, R. S., & Shirwan, H. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.09.127 · Cited by 58
“For example, a single intravenous dose of a superagonist anti-CD28 mAb in 6 healthy volunteers enrolled in a Phase I clinical trial resulted in a systemic inflammatory response and life threatening toxicity [8].”
BackgroundIdentifying and hurdling obstacles to translational research
Sabroe, I., Dockrell, D. H., Vogel, S. N., Renshaw, S. A., Whyte, M. K. B., & Dower, S. (2006) · Nature reviews. Immunology · doi:10.1038/nri1999 · Cited by 59
“Recently, differential expression of SIGLECs (sialicacid-binding immunoglobulin-like lectins), which are inhibitory receptors thought to downregulate immune-cell activation, has been noted between apes and humans 16 , and such differences in immune responses between species require careful consideration, as highlighte…”
BackgroundBiomaterials and Culture Systems for Development of Organoid and Organ-on-a-Chip Models
D’Costa, K. A., Kosic, M., Lam, A., Moradipour, A., Zhao, Y., & Radisic, M. (2020) · Annals of Biomedical Engineering · doi:10.1007/s10439-020-02498-w · Cited by 55
Publication bias in the medical literature: A review by a Canadian research ethics board
Hall, R., de Antueno, C., & Webber, A. (2007) · Canadian Journal of Anesthesia · doi:10.1007/bf03022661 · Cited by 54
Pharmacovigilance of Biopharmaceuticals
Giezen, T. J., Mantel-Teeuwisse, A. K., & Leufkens, H. G. M. (2009) · Drug Safety · doi:10.2165/11316550-000000000-00000 · Cited by 54
SARS-CoV-2/COVID-19: Evolving Reality, Global Response, Knowledge Gaps, and Opportunities
Osuchowski, M. F., Aletti, F. M., Cavaillon, J., Flohé, S. B., Giamarellos‐Bourboulis, E. J., Huber-Lang, M. S., Relja, B., Skirecki, T., Szabó, A., & Maegele, M. (2020) · Shock · doi:10.1097/shk.0000000000001565 · Cited by 59
“Compared with hyperreactive responses recorded in bacterial septic patients (79) and after noninfectious triggers (80), the cytokine upregulation in COVID-19 appears to be at least one log of magnitude lower.”
BackgroundPotential Applications and Perspectives of Humanized Mouse Models
Ye, W., & Chen, Q. (2021) · Annual Review of Animal Biosciences · doi:10.1146/annurev-animal-020420-033029 · Cited by 64
Clarifying the Mechanism of Superantigen Toxicity
Fraser, J. D. (2011) · PLoS Biology · doi:10.1371/journal.pbio.1001145 · Cited by 65
“This is best highlighted by the unfortunate 2006 clinical trial of the company TeGenero’s humanised anti-CD28 monoclonal antibody TGN1412: unexpectedly all six healthy volunteers suffered near fatal toxic shock immediately following PLoS Biology | www.plosbiology.org 2 September 2011 | Volume 9 | Issue 9 | e1001145 in…”
BackgroundGiri, S., & Bader, A. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.10.011 · Cited by 67
Quantitative Prediction of Human Pharmacokinetics for mAbs Exhibiting Target-Mediated Disposition
Singh, A. P., Krzyżański, W., Martin, S. W., Weber, G. L., Betts, A. M., Ahmad, A. M., Abraham, A. K., Zutshi, A., Lin, J., & Singh, P. (2014) · The AAPS Journal · doi:10.1208/s12248-014-9690-8 · Cited by 58
“Several recent cases highlight this challenge such as progressive multifocal leukoencephalopathy (PML) observed with natalizumab (6), reactivation of Epstein-Barr virus (EBV) with anti-CD3 mAb (7), and the occurrence of cytokine storm with an anti-CD28 super agonist (8).”
BackgroundAn FDA oncology analysis of immune activating products and first-in-human dose selection
Saber, H., Gudi, R., Manning, M. L., Wearne, E., & Leighton, J. K. (2016) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2016.10.002 · Cited by 55
Biosimilars entering the clinic without animal studies: A paradigm shift in the European Union
van Aerts, L., Smet, K. D., Reichmann, G., van der Laan, J. W., & Schneider, C. K. (2014) · mAbs · doi:10.4161/mabs.29848 · Cited by 62
“, in certain oncology conditions where lymphocytes are targeted, or as a result of human-specific response due to differences in T-cell reactivity to a drug, as was the case in the TGN1412 event.(18,19) Infusion reactions, which are also associated with the release of cytokines, may be triggered by different causes, i…”
BackgroundA more selective costimulatory blockade of the CD28-B7 pathway
Poirier, N., Blancho, G., & Vanhove, B. (2010) · Transplant International · doi:10.1111/j.1432-2277.2010.01176.x · Cited by 54
“The phase I clinical trial of this molecule as a potential immunotherapeutic for the treatment of chronic lymphocytic B-cell leukemia proved to be catastrophic because TGN1412, unexpectedly, provoked a rapid and massive cytokine storm that caused severe and life-threatening adverse effects [84].”
BackgroundCancer immunotherapy via nucleic acid aptamers
Khedri, M., Rafatpanah, H., Abnous, K., Ramezani, P., & Ramezani, M. (2015) · International Immunopharmacology · doi:10.1016/j.intimp.2015.10.013 · Cited by 55
Bispecific Antibodies and Trispecific Immunocytokines for Targeting the Immune System Against Cancer
Fournier, P., & Schirrmacher, V. (2012) · BioDrugs · doi:10.1007/s40259-012-0008-z · Cited by 58
Grimaldi, C. M., Finco, D., Fort, M. M., Gliddon, D., Harper, K., Helms, W. S., Mitchell, J. A., O’Lone, R. B., Parish, S. T., Piché, M.-S., et al. (2016) · Cytokine · doi:10.1016/j.cyto.2016.06.006 · Cited by 55
Cytokine release syndrome after radiation therapy: case report and review of the literature
Barker, C. A., Kim, S. K., Budhu, S., Matsoukas, K., Daniyan, A. F., & D’Angelo, S. P. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0311-9 · Cited by 52
Boczkowski, D., Lee, J., Pruitt, S. K., & Nair, S. K. (2009) · Cancer Gene Therapy · doi:10.1038/cgt.2009.39 · Cited by 53
Bailey, J., & Balls, M. (2019) · BMC Medical Ethics · doi:10.1186/s12910-019-0352-3 · Cited by 51
Suh, H. Y., Peck, C., Yu, K.-S., & Lee, H. (2016) · Drug Design, Development and Therapy · doi:10.2147/dddt.s121520 · Cited by 51
“6 After the incident in the FIH study of TGN1412, several publications have proposed various ways to determine MRSD for FIH studies with biological agents.”
BackgroundExploring the dark genome: implications for precision medicine
Oprea, T. I. (2019) · Mammalian Genome · doi:10.1007/s00335-019-09809-0 · Cited by 50
“When developing therapeutic monoclonal antibodies (mAbs), a different set of informatics and data wrangling needs (Mould and Meibohm 2016) arise: in-depth understanding of safety, pharmacokinetics, and pharmacodynamics in order to avoid side effects such as the “cytokine storm” (Suntharalingam et al. 2006), in combina…”
CD69 is a Promising Immunotherapy and Prognosis Prediction Target in Cancer
Li, Y., Gu, Y., Yang, P., Wang, Y., Yu, X., Li, Y., Jin, Z., & Xu, L. (2024) · ImmunoTargets and Therapy · doi:10.2147/itt.s439969 · Cited by 59
New Insights into Adaptive Immunity in Chronic Neuroinflammation
Siffrin, V., Brandt, A. U., Herz, J., & Zipp, F. (2007) · Advances in immunology · doi:10.1016/s0065-2776(07)96001-0 · Cited by 58
Balancing Justice and Autonomy in Clinical Research With Healthy Volunteers
KASS, N. E., Myers, R. K., Fuchs, E. J., Carson, K. A., & Flexner, C. W. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100192 · Cited by 52
Targeting Regulatory T Cells in the Treatment of Type 1 Diabetes Mellitus
Cabrera, S. M., Rigby, M. R., & Mirmira, R. G. (2012) · Current Molecular Medicine · doi:10.2174/156652412803833634 · Cited by 55
“Notably, low-dose IL-2 treatment minimized the effect of IL-2 on NK and Teff cells, reducing the incidence of cytokine stormseen with higher dose IL-2 agonists [65, 127, 128].”
BackgroundToxicity as a result of immunostimulation by biologics
Gribble, E. J., Sivakumar, P. V., Ponce, R. A., & Hughes, S. D. (2007) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.3.2.209 · Cited by 52
“Anti-inflammatory agents, such as steroids, can be effective in controlling this response [119,120].”
BackgroundChen, W. H., Pasetti, M. F., Adhikari, R. P., et al. (2016) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00399-16 · Cited by 51
“Due to concerns for wide-scale T-cell activation and an overwhelming cytokine storm, as was seen with the infusion of a CD28 superagonist (26), we carefully selected the starting dose (0.”
BackgroundKean, L. S., Turka, L. A., & Blazar, B. R. (2017) · Immunological Reviews · doi:10.1111/imr.12523 · Cited by 52
Staphylococcus aureus Host Tropism and Its Implications for Murine Infection Models
Mrochen, D. M., de Oliveira, L. M. F., Raafat, D., & Holtfreter, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197061 · Cited by 64
“A CD28-superagonist, which activated and expanded anti-inflammatory regulatory T cells in conventional laboratory mice and showed promising results in autoimmune disease, inflammatory disease, and transplantation models, led to a life-threatening cytokine storm in human phase I clinical trials [239].”
BackgroundLost in Translation: Bumps in the Road Between Bench and Bedside
Levin, L. A., & Danesh-Meyer, H. V. (2010) · JAMA · doi:10.1001/jama.2010.463 · Cited by 50
“For instance, superagonist anti-CD28 antibodies had been tested in rats and monkeys without significant adverse effects, but were almost deadly when administered to humans, resulting in cytokine storm and multiorgan failure in 6 previously healthy volunteers.(6) What underlies this chaotic behavior that appears to be…”
BackgroundAdigbli, G., Ménoret, S., Cross, A. R., Hester, J., Issa, F., & Anegón, I. (2020) · Transplantation · doi:10.1097/tp.0000000000003177 · Cited by 55
“However, it is increasingly clear that the mechanistic gap between human and small animal immune responses is significant, leading to challenges in the translation of findings from animal to human that can, on occasion, have devastating results.(1,2,3) Humanized laboratory animals have been developed to bridge this ga…”
Nashiry, M. A., Sumi, S. S., Islam, S., Quinn, J. M. W., & Moni, M. A. (2020) · Briefings in Bioinformatics · doi:10.1093/bib/bbaa426 · Cited by 54
NF-κB family of transcription factors: Biochemical players of CD28 co-stimulation
Tuosto, L. (2010) · Immunology Letters · doi:10.1016/j.imlet.2010.09.005 · Cited by 55
“IFN- and TNF- ), thus causing a systemic inflammatory response syndrome during phase I clinical trial [99].”
BackgroundDu, X., Nagata, S., Ise, T., et al. (2007) · Blood · doi:10.1182/blood-2007-07-102350 · Cited by 50
Perry, L., Jones, T. D., & Baker, M. (2008) · Drugs in R&D · doi:10.2165/0126839-200809060-00004 · Cited by 51
Ly, L. V., Sluijter, M., Versluis, M., Luyten, G. P. M., van der Burg, S. H., Melief, C. J. M., Jager, M. J., & van Hall, T. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-2288 · Cited by 50
Precaution, cyclooxygenase inhibition, and cardiovascular risk
Ritter, J. M., Harding, I., & Warren, J. B. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.07.007 · Cited by 52
Regulatory T Cells in Atherogenesis
Sasaki, N., Yamashita, T., Takeda, M., & Hirata, K. (2012) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.10934 · Cited by 55
Pridgeon, C. S., Schlott, C., Wong, M. W., Heringa, M. B., Heckel, T., Leedale, J., Launay, L., Gryshkova, V., Przyborski, S. A., Bearon, R. N., et al. (2018) · Archives of Toxicology · doi:10.1007/s00204-018-2152-9 · Cited by 55
“More recent examples include the TGN1412 trial, where despite the use of animal studies for the novel immunomodulatory antibody CD28 ‘superagonist’ and use of a dose 500 times lower than found to be safe in animals, all six of the patients suffered from cytokine storm and were hospitalised (Suntharalingam et al. 2006).”
BackgroundSystemic cancer therapy: Evolution over the last 60 years
Dy, G. K., & Adjei, A. A. (2008) · Cancer · doi:10.1002/cncr.23651 · Cited by 65
“failure arising from severe hypersensitivity reaction.(198) This triggered the temporary suspension of clinical trials involving immunomodulatory drugs in the UK in early 2006.”
BackgroundImmunological Responses to Envenomation
Ryan, R. Y. M., Seymour, J., Loukas, A., Lopez, J. A., Ikonomopoulou, M. P., & Miles, J. J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.661082 · Cited by 49
Wolf, B., Morgan, H., Krieg, J., Gani, Z., Milicov, A., Warncke, M., Brennan, F. R., Jones, S., Sims, J., & Kießling, A. (2012) · Cytokine · doi:10.1016/j.cyto.2012.08.018 · Cited by 50
Mei, H., Jiang, H., Wu, Y., Guo, T., Xia, L., Jin, R., & Hu, Y. (2017) · British Journal of Haematology · doi:10.1111/bjh.14680 · Cited by 53
Biotherapeutics: Challenges and Opportunities for Predictive Toxicology of Monoclonal Antibodies
Johnson, D. E. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113685 · Cited by 53
“Examples include the TGN1412 incident [22] with direct stimulation of T cells and a resulting cytokine storm; and muromomab and OKT3, resulting in significantly increased TNF-α serum levels [6].”
BackgroundReviewing the role of healthy volunteer studies in drug development
Karakunnel, J. J., Bui, N. Q., Palaniappan, L. P., Schmidt, K. T., Mahaffey, K. W., Morrison, B. W., Figg, W. D., & Kummar, S. (2018) · Journal of Translational Medicine · doi:10.1186/s12967-018-1710-5 · Cited by 55
In vitro Models of the Small Intestine for Studying Intestinal Diseases
Jung, S.-M., & Kim, S. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.767038 · Cited by 54
A Novel Antibody–4-1BBL Fusion Protein for Targeted Costimulation in Cancer Immunotherapy
Müller, D., Frey, K., & Kontermann, R. E. (2008) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31818353e9 · Cited by 52
“Suntharalingam G, Perry MR, Ward S, et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412.”
BackgroundThe Complex Clinical Picture of Side Effects to Biologicals
Hausmann, O. V., Seitz, M., Villiger, P. M., & Pichler, W. J. (2010) · Medical Clinics of North America · doi:10.1016/j.mcna.2010.03.001 · Cited by 47
Dose Selection in Preclinical Studies: Cross-Species Dose Conversion
Шекунова, Е. В., Kovaleva, M. А., Макарова, М. Н., & Makarov, V. G. (2020) · The Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products Regulatory Research and Medicine Evaluation · doi:10.30895/1991-2919-2020-10-1-19-28 · Cited by 60
Inhaled innate immune ligands to prevent pneumonia
Evans, S. E., Tuvim, M. J., Fox, C. J., Sachdev, N., Gibiansky, L. V., & Dickey, B. F. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01237.x · Cited by 54
Efficiency of T‐cell costimulation by CD80 and CD86 cross‐linking correlates with calcium entry
Thiel, M., Wolfs, M., Bauer, S., Wenning, A. S., Burckhart, T., Schwarz, E. C., Scott, A. M., Renner, C., & Hoth, M. (2009) · Immunology · doi:10.1111/j.1365-2567.2009.03155.x · Cited by 56
Adverse drug reactions to biologics
Scherer, K., Spoerl, D., & Bircher, A. J. (2010) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/j.1610-0387.2010.07339.x · Cited by 53
Cancer immunotherapy trials: leading a paradigm shift in drug development
Emens, L. A., Butterfield, L. H., Hodi, F. S., Marincola, F. M., & Kaufman, H. L. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0146-9 · Cited by 50
“TeGenero developed a first-in-class humanized superagonist monoclonal antibody specific for CD28, TGN1412 [12, 13].”
BackgroundLaptoš, T., & Omersel, J. (2018) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2018.5821 · Cited by 75
“This was later recognized to have been the result of cytokine storm (31).”
Fergusson, J. R., Wallace, Z., Connolly, M. M., Woon, A. P., Suckling, R. J., Hine, D. W., Barber, C., Bunjobpol, W., Choi, B., Crespillo, S., et al. (2020) · Hepatology · doi:10.1002/hep.31503 · Cited by 52
“Importantly, the activity of ImmTAV-Env is shown to be dose dependent and its induction of cytokines can be downmodulated by the addition of dexamethasone, which may be used in the event of CRS (22, 23).”
BackgroundThe rise and fall of the CD 28 superagonist TGN 1412 and its return as TAB 08: a personal account
Hünig, T. (2016) · The FEBS Journal · doi:10.1111/febs.13754 · Cited by 47
CD28-Specific Immunomodulating Antibodies: What Can Be Learned From Experimental Models?
Poirier, N., Blancho, G., & Vanhove, B. (2012) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2012.04032.x · Cited by 52
“11A1 Superagonist Hz-mouse Increases thymic production but induces peripheral T-cell depletion (11) Induces transient accumulation of Tregs (11) TGN1412 Superagonist Monkey Does not induce calcium responses in T cells (27) Does not induce massive cytokine release but induces T-cells activation (23) Human Induces cytok…”
BackgroundMasterful Antibodies: Checkpoint Blockade
Lönberg, N., & Korman, A. J. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0057 · Cited by 52
“Human antibodies to CTLA-4 were screened for their ability to inhibit the interaction between CTLA-4 and B7 ligands while showing no reactivity with CD28 and little to no cross-reactivity with normal tissues.”
BackgroundButler, L. D., Guzzie‐Peck, P., Hartke, J., Bogdanffy, M. S., Will, Y., Diaz, D., Mortimer‐Cassen, E., Derzi, M., Greene, N., & DeGeorge, J. J. (2017) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2017.05.009 · Cited by 51
Immune-Related Adverse Events in Cancer Patients Treated With Immune Checkpoint Inhibitors
Sandigursky, S., & Mor, A. (2018) · Current Rheumatology Reports · doi:10.1007/s11926-018-0770-0 · Cited by 53
Abboud, R., Wan, F., Mariotti, J., Arango, M., Castagna, L., Romee, R., Hamadani, M., & Chhabra, S. (2021) · Bone Marrow Transplantation · doi:10.1038/s41409-021-01403-w · Cited by 50
Quality-control issues and approaches in vaccine development
Metz, B., van den Dobbelsteen, G., van Els, C. A. C. M., van der Gun, J., Levels, L., van der Pol, L., Rots, N. Y., & Kersten, G. F. A. (2009) · Expert Review of Vaccines · doi:10.1586/14760584.8.2.227 · Cited by 54
Pillai, V., & Karandikar, N. J. (2007) · Immunology Letters · doi:10.1016/j.imlet.2007.08.012 · Cited by 55
“Such an unfortunate sequence of events may have been exemplified by the recent anti-CD28 super agonist (TGN1412) trial where attempts to expand Tregs in humans, based on in vitro FOXP3 and suppression readouts, ended in untoward consequences [61], including a massive cytokine storm from unrestrained T cell activation…”
BackgroundKretz-Rommel, A., & Bowdish, K. S. (2007) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.8.1.5 · Cited by 52
Performance-based readability testing of participant materials for a phase I trial: TGN1412: Table 1
Knapp, P., Raynor, D. K., Silcock, J., & Parkinson, B. (2009) · Journal of Medical Ethics · doi:10.1136/jme.2008.026708 · Cited by 51
A CD28 superagonistic antibody elicits 2 functionally distinct waves of T cell activation in rats
Müller, N., van den Brandt, J., Odoardi, F., Tischner, D., Herath, J., Flügel, A., & Reichardt, H. M. (2008) · Journal of Clinical Investigation · doi:10.1172/jci32698 · Cited by 46
Rhee, A. J., & Lavine, K. J. (2020) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021119-034412 · Cited by 46
The New Era of Cancer Immunotherapy
Khalil, D. N., Budhu, S., Gasmi, B., Zappasodi, R., Hirschhorn-Cymerman, D., Plitt, T., Henau, O. D., Zamarin, D., Holmgaard, R., Murphy, J. T., et al. (2015) · Advances in cancer research · doi:10.1016/bs.acr.2015.04.010 · Cited by 51
Neaga, A., Lefor, J., Lich, K. E., Liparoto, S. F., & Xiao, Y. Q. (2011) · Journal of Immunological Methods · doi:10.1016/j.jim.2011.06.027 · Cited by 46
“The safety issue of the first-in-human phase 1 study of TGN1412, a novel humanized anti-CD28 monoclonal antibody was a prevalent example (Suntharalingam et al., 2006; Giezen et al., 2008).”
Emanuel, E. J., & Miller, F. G. (2007) · The American Journal of Bioethics · doi:10.1080/15265160601111800 · Cited by 49
“Respecting enrolled participants: Were the participants closely monitored and did they have their rights protected in the conduct of the research? The health of the research participants was closely monitored; the biological agent was administered in a hospital, and they were immediately treated appropriately for coma…”
BackgroundAptamers and Glioblastoma: Their Potential Use for Imaging and Therapeutic Applications
Hays, E., Duan, W., & Shigdar, S. L. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18122576 · Cited by 49
Park, J. A., Santich, B. H., Xu, H., Lum, L. G., & Cheung, N. V. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002222 · Cited by 50
Targeting T Cells with Bispecific Antibodies for Cancer Therapy
Lum, L. G., & Thakur, A. B. (2011) · BioDrugs · doi:10.2165/11595950-000000000-00000 · Cited by 46
Vukelic, M., Li, Y., & Kyttaris, V. C. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02658 · Cited by 49
For the Common Good: Philosophical Foundations of Research Ethics
London, A. J. (2021) · doi:10.1093/oso/9780197534830.001.0001 · Cited by 107
Donor-Reactive T-Cell Stimulation History and Precursor Frequency: Barriers to Tolerance Induction
Ford, M. L., Kirk, A. D., & Larsen, C. P. (2009) · Transplantation · doi:10.1097/tp.0b013e3181a2a701 · Cited by 45
Targeting CD8 + T-cell Tolerance for Cancer Immunotherapy
Jackson, S. R., Yuan, J., & Teague, R. M. (2014) · Immunotherapy · doi:10.2217/imt.14.51 · Cited by 51
Primate testing of TGN1412: right target, wrong cell
Pallardy, M. J., & Hünig, T. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00925.x · Cited by 45
“What happened was an unexpected cytokine release syndrome encountered during a first-inman trial of TGN1412, a fully humanized monoclonal antibody (mAb) specific for CD28 (Suntharalingam et al., 2006).”
BackgroundDevelopment and Characterization of Monoclonal Antibodies Specific for Mouse and Human Fcγ Receptors
Tutt, A. L., James, S., Laversin, S. A., Tipton, T. R. W., Ashton‐Key, M., French, R. R., Hussain, K., Vaughan, A. T., Dou, L., Earley, A., et al. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402988 · Cited by 53
Novel Immunotherapeutic Avenues for Rheumatoid Arthritis
Semerano, L., Minichiello, É., Bessis, N., & Boissier, M. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.01.005 · Cited by 49
“With these findings supporting a differential sensitivity of Tregs versus Teffs to CD28SA, a Phase I study of TAB08 for RA is currently ongoing [39].”
BackgroundInfluentialShi, R., Honczarenko, M., Zhang, S. X., Fleener, C., Mora, J. R., Lee, S. K., Wang, R., Liu, X., Shevell, D. E., Yang, Z., et al. (2016) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.791 · Cited by 44
“However, this agent led to lifethreatening cytokine storms in six healthy volunteers during first-in-human research.(7) Subsequent work identified CD4+ effector memory cells—common in human tissues but lacking in CD28 expression among cynomolgus monkeys, which were used in preclinical evaluation—as the source of toxic…”
BackgroundAnderson, R., & Rapoport, B. L. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00080 · Cited by 47
“TGN1412, also known as CD28 SuperMAB/TAB 08, promotes antigen-independent activation and expansion of T cells via its agonistic interaction with the co-stimulatory molecule CD28.”
BackgroundInfluentialSummary of a workshop on preclinical and translational safety assessment of CD3 bispecifics
Kamperschroer, C., Shenton, J. M., Lebrec, H. N., Leighton, J. K., Moore, P. A., & Thomas, O. (2020) · Journal of Immunotoxicology · doi:10.1080/1547691x.2020.1729902 · Cited by 46
Mechanisms of Adverse Drug Reactions to Biologics
Clarke, J. B. (2009) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-00663-0_16 · Cited by 48
“In 2006, a phase I trial with a superagonist monoclonal antibody to CD28 (TGN1412) in six healthy volunteers produced life-threatening adverse events that required intensive care (Suntharalingam et al. 2006).”
BackgroundImmunotherapy resistance in solid tumors: mechanisms and potential solutions
Lefler, D. S., Manobianco, S. A., & Bashir, B. (2024) · Cancer Biology & Therapy · doi:10.1080/15384047.2024.2315655 · Cited by 56
“91 However, there are still models of combined 4-1BB stimulation and PD-1 inhibition that have some promise due to anti-tumor effect.”
BackgroundPărângă, T. G., Mitu, I., Tanasa, M. P., Roșu, M. F., Miftode, I.-L., Constantinescu, D., Obreja, M., Plesca, C. E., & Miftode, E. G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252111411 · Cited by 57
“The latter targeted therapy response is known in oncology as cytokine release syndrome, which encompasses CS and highlights the pluripotent role of cytokines in human pathophysiology [4].”
BackgroundBurnouf, T. (2010) · Vox Sanguinis · doi:10.1111/j.1423-0410.2010.01384.x · Cited by 53
Dhir, V., Fort, M., Mahmood, A., Higbee, R., Warren, W., Narayanan, P., & Wittman, V. (2012) · Journal of Immunotoxicology · doi:10.3109/1547691x.2011.613419 · Cited by 44
“However, in 2006, it became clear that human WB or PBMC assays are not always predictive of in vivo CRS: the initial dose of a proposed immunosuppressive mAb therapeutic, TGN1412, which targets CD28 on T-lymphocytes, caused severe CRS during a first-in-human clinical trial despite causing no cytokine release or T-lymp…”
BackgroundMethodResultInfluentialUrbańska, K., Lynn, R. C., Stashwick, C., Thakur, A. B., Lum, L. G., & Powell, D. J. (2014) · Journal of Translational Medicine · doi:10.1186/s12967-014-0347-2 · Cited by 47
“However, this kind of systemic activation of the costimulatory ligand was accompanied by unexpected systemic toxicities in vivo, as observed after superagonistic anti-CD28 mAb TGN1412 application [50,51].”
BackgroundSakanishi, T., & Yagita∥, H. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.02.092 · Cited by 44
Vaccine Immunopotentiators of the Future
Schijns, V. E. J. C., & Degen, W. G. J. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100394 · Cited by 44
“Striking unintended effects were recently observed in an anti-CD28 antibody trial”
BackgroundAgents to reduce cytokine storm
Gerlach, H. (2016) · F1000Research · doi:10.12688/f1000research.9092.1 · Cited by 47
Toxicity testing: the search for an in vitro alternative to animal testing
May, J. E., Xu, J., Morse, H. R., Avent, N. D., & Donaldson, C. (2009) · British Journal of Biomedical Science · doi:10.1080/09674845.2009.11730265 · Cited by 43
Haanstra, K. G., Dijkman, K., Bashir, N., Bauer, J., Mary, C., Poirier, N., Baker, P., Scobie, L., Hart, B. A. ‘., & Vanhove, B. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402563 · Cited by 43
Ramachandran, G., Kaempfer, R. O. R., Chung, C., Shirvan, A., Chahin, A. B., Palardy, J. E., Parejo, N. A., Chen, Y., Whitford, M., Arad, G., et al. (2014) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiu556 · Cited by 43
“Unlike TGN1412, an agonist monoclonal antibody that cross-links the CD28 coreceptor and caused a cytokine storm and organ failure in a phase 1 clinical trial study [18], AB103 is”
Background
Metadata
- Authors
- Suntharalingam, G., Perry, M. R., Ward, S., Brett, S. J., Castello-Cortes, A., Brunner, M. D., & Panoskaltsis, N.
- Affiliations
- Hammersmith Hospital (GB)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-09-07
- Volume
- 355
- Issue
- 10
- Pages
- 1018-1028
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2141989396
- Cited by
- 2,164
- References
- 18
- Citations by year
- 2026: 57 · 2025: 73 · 2024: 95 · 2023: 79 · 2022: 79 · 2021: 120 · 2020: 141 · 2019: 94 · 2018: 102 · 2017: 97 · 2016: 117 · 2015: 122 · 2014: 118 · 2013: 120 · 2012: 114
- FWCI
- 80.54
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Health Sciences › Medicine › Hematology › Autoimmune and Inflammatory Disorders Research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotoxicology and immune responses
- Keywords
- cytokine release syndrome, TGN1412, anti-CD28 monoclonal antibody, systemic inflammatory response syndrome, inflammatory cytokines, acute respiratory distress syndrome, disseminated intravascular coagulation, renal failure, drug-induced immunotoxicity
- MeSH terms
- Adult, Antibodies, Monoclonal, C-Reactive Protein, Critical Care, Double-Blind Method, Hemodynamics, Humans, Hypotension, Infusions, Intravenous, Leukopenia, Male, Multiple Organ Failure, Thrombocytopenia, Cytokines, CD28 Antigens, Disease Progression, APACHE, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.